SCHEMBL214641

SCHEMBL214641

CC(=N)N[C@@H](CCCCN)C(=O)O

nearest known ligand 0.58

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
FOLH1 Q04609 2/20 0.58
SLC6A5 Q9Y345 1/20 0.49
GSR P00390 1/20 0.46
RNPEP Q9H4A4 1/20 0.44
SIRT6 Q8N6T7 1/20 0.43
SIRT1 Q96EB6 1/20 0.43
CPB2 Q96IY4 10/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
MMP2 P08253 1/20 0.41
MMP9 P14780 1/20 0.41
GNPAT O15228 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL45765 1.00 FOLH1 (0.58) FOLH1SLC6A5GSRRNPEPSIRT6
Hydrochloric Acid SCHEMBL2166126 0.98 FOLH1 (0.57) FOLH1SLC6A5GSRRNPEPSIRT6
Hydrochloric Acid SCHEMBL15914484 0.98 FOLH1 (0.57) FOLH1SLC6A5GSRRNPEPSIRT6
Acetic Acid SCHEMBL268740 0.98 FOLH1 (0.57) FOLH1SLC6A5GSRRNPEPSIRT6
SCHEMBL867577 0.95 FOLH1 (0.51) FOLH1SLC6A5GSRRNPEPSIRT6
SCHEMBL866580 0.95 FOLH1 (0.51) FOLH1SLC6A5GSRRNPEPSIRT6
SCHEMBL232125 0.95 FOLH1 (0.51) FOLH1SLC6A5GSRRNPEPSIRT6
Hydrochloric Acid SCHEMBL1982438 0.93 FOLH1 (0.50) FOLH1SLC6A5GSRSIRT6SIRT1
Hydrochloric Acid SCHEMBL1982441 0.93 FOLH1 (0.50) FOLH1SLC6A5GSRSIRT6SIRT1
SCHEMBL919220 0.85 FOLH1 (0.62) FOLH1SLC6A5GSRRNPEPSIRT6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 197 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140154207-A1 KIT CONTAINING STEM CELLS AND CYTOKINES FOR USE IN ATTENUATING IMMUNE RESPONSES RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2014-06-05 US claimed
US-20130123364-A1 N6-(1-IMINOETHYL)-L-LYSINE FOR REGENERATION OF ALVEOLI IN LUNGS WEISSMANN NORBERT (DE) 2013-05-16 US claimed
US-8183409-B2 High yield and rapid synthesis methods for producing metallo-organic salts OSTEOLOGIX A/S (DK) 2012-05-22 US claimed
US-8088150-B2 Device for disc shunt implantation and peri-shunt injection ALEEVA MEDICAL INC. (US) 2012-01-03 US claimed
US-20090325858-A1 Reduction of Zinc-Induced Neurotoxic Injury By Blockade of Nitric Oxide Synthesis ANDRO DIAGNOSTICS, INC. (US) 2009-12-31 US claimed
US-20090291926-A1 HIGH YIELD AND RAPID SYNTHESIS METHODS FOR PRODUCING METALLO-ORGANIC SALTS CHRISTGAU STEPHAN 2009-11-26 US claimed
US-20090198248-A1 Device for disc shunt implantation and peri-shunt injection YEUNG JEFFREY E 2009-08-06 US claimed
US-20080317849-A1 Method for Improving the Medical Treatment of Pain OSTEOLOGIX A/S (DK) 2008-12-25 US claimed
EP-1534313-A4 OPHTHALMOLOGIC IRRIGATION SOLUTIONS AND METHOD OMEROS CORP (US) 2008-06-25 EP claimed
US-20070282127-A1 High Yield And Rapid Synthesis Methods For Producing Metallo-Organic Salts OSTEOLOGIX A/S 2007-12-06 US claimed
US-5686567-A OLIGOPEPTIDES, SNAKE VENOM COR THERAPEUTICS, INC. (US) 1997-11-11 US claimed
WO-1997032585-A1 COMBINATIONAL THERAPEUTIC METHODS EMPLOYING NITRIC OXIDE SCAVENGERS AND COMPOSITIONS USEFUL THEREFOR MEDINOX, INC. (US) 1997-09-12 WO claimed
WO-1997018805-A1 COMBINATIONAL THERAPEUTIC METHODS EMPLOYING NITRIC OXIDE SCAVENGERS MEDINOX, INC. (US) 1997-05-29 WO claimed
EP-0751219-A1 Platelet aggregation inhibitors COR THERAPEUTICS, INC. (US) 1997-01-02 EP claimed
EP-0477295-B1 PLATELET AGGREGATION INHIBITORS COR THERAPEUTICS INC (US) 1997-01-02 EP claimed
EP-0639202-A1 STABLE POLYPEPTIDE COMPOSITION COR THERAPEUTICS, INC. (US) 1995-02-22 EP claimed
WO-1993022335-A1 STABLE POLYPEPTIDE COMPOSITION COR THERAPEUTICS, INC. (US) 1993-11-11 WO claimed
EP-0477295-A4 PLATELET AGGREGATION INHIBITORS 1992-10-07 EP claimed
EP-0477295-A1 PLATELET AGGREGATION INHIBITORS. COR THERAPEUTICS INC (US) 1992-04-01 EP claimed
WO-1990015620-A1 PLATELET AGGREGATION INHIBITORS COR THERAPEUTICS, INC. (US) 1990-12-27 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130123364-A1 N6-(1-IMINOETHYL)-L-LYSINE FOR REGENERATION OF ALVEOLI IN LUNGS PRMT1, ARG1, ARGLU1 FOLH1 1155/4885SLC6A5 3250/4885GSR 2375/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.